6-K

Sofgen Pharma S.A. (PROCF)

6-K 2025-08-01 For: 2025-08-01
View Original
Added on April 06, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K


REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934



For the month of August 2025


2024 Commission File Number: 001-40851


Procaps Group, S.A.

(Translation of registrant’s name in English)



9 rue de Bitbourg, L-1273

Luxembourg

Grand Duchy of Luxembourg

R.C.S. Luxembourg: B253360

Tel: +356 7995-6138

(Address of Principal Executive Offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ **** Form 40-F ☐


INFORMATION CONTAINEDIN THIS REPORT ON FORM 6-K

Departure of Dr. Camilo Camacho


On July 25, 2025, the Board of Directors (the “Board”) of Procaps Group, S.A., a public limited liability company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg (the “Company” or “Procaps”), notified Dr. Camilo Camacho that he was relieved of his duties as Interim Co-Chief Executive Officer of the Company, effective immediately.

Appointment of Chief Commercial Officer

On July 25, 2025, the Board of the Company appointed Mr. Luis Palacios as Chief Commercial Officer of the Company

1

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PROCAPS GROUP, S.A.
By: /s/ Melissa Angelini
Name: Melissa Angelini
Title: Interim Co-Chief Executive Officer

Dated: August 1, 2025


2